US and German biotechnology companies Pfizer and BioNTech have announced that their experimental vaccine against Covid-19 has been tested “95% effective” in the final results of a pivotal study, and shows reassuring signs of safety.
Pfizer plans to seek authorization for the vaccine in the coming days, which leaves it on track to be distributed by the end of the year once authorized, according to US media.
For comparison, the 95% efficacy rate of Pfizer’s vaccine is equal to that of herpes zoster and measles vaccines, especially since the researchers did not detect any serious safety issues during the phases of tests, according to the American company.
The vaccine also appeared to be well tolerated after a review of data from 8,000 study subjects, the two companies said, adding that a serious side effect was fatigue, reported by 3.8% of subjects, while 2% of subjects reported headaches.
The US administration has funded $ 9 billion for research conducted by several vaccine developers in the hope of being able to immunize all Americans.
Since the start of the pandemic in the United States last March, more than 11 million Covid-19 infections have been identified in the country, which is the most bereaved in the world by the virus, with more than 248,000 deaths.